Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01006980 · BASELINE

Baseline characteristics

A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) · Source last updated 2016-09-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      337
    2. group Id
      BG001
      value
      338
    3. group Id
      BG002
      value
      675
    units
    Participants
groups
  1. description
    Participants received continuous oral doses of vemurafenib (RO5185426) 960 mg twice a day. Participants took four 240 mg tablets in the morning and four 240 mg tablets in the evening (960 mg twice a day for a total daily dose of 1920 mg).
    id
    BG000
    title
    Vemurafenib
  2. description
    Dacarbazine was administered intravenously 1000 mg/m˄2 up to 60 minutes on Day 1 of every 3 weeks (3 weeks was one cycle length).
    id
    BG001
    title
    Dacarbazine
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          244
        2. group Id
          BG001
          value
          270
        3. group Id
          BG002
          value
          514
      title
      < 65 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          93
        2. group Id
          BG001
          value
          68
        3. group Id
          BG002
          value
          161
      title
      >=65 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          137
        2. group Id
          BG001
          value
          157
        3. group Id
          BG002
          value
          294
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          200
        2. group Id
          BG001
          value
          181
        3. group Id
          BG002
          value
          381
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      337
    2. group Id
      BG001
      value
      338
    3. group Id
      BG002
      value
      675
    units
    Participants
groups
  1. description
    Participants received continuous oral doses of vemurafenib (RO5185426) 960 mg twice a day. Participants took four 240 mg tablets in the morning and four 240 mg tablets in the evening (960 mg twice a day for a total daily dose of 1920 mg).
    id
    BG000
    title
    Vemurafenib
  2. description
    Dacarbazine was administered intravenously 1000 mg/m˄2 up to 60 minutes on Day 1 of every 3 weeks (3 weeks was one cycle length).
    id
    BG001
    title
    Dacarbazine
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          244
        2. group Id
          BG001
          value
          270
        3. group Id
          BG002
          value
          514
      title
      < 65 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          93
        2. group Id
          BG001
          value
          68
        3. group Id
          BG002
          value
          161
      title
      >=65 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          137
        2. group Id
          BG001
          value
          157
        3. group Id
          BG002
          value
          294
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          200
        2. group Id
          BG001
          value
          181
        3. group Id
          BG002
          value
          381
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice